California cannabis DEA registration
How the federal medical marijuana registration pathway at 21 C.F.R. § 1301.13(k) applies to a Department of Cannabis Control licensee, what has changed since the priority window closed in June 2026, and the California-specific questions the DEA is now asking: the adult-use and medicinal split, patient certification, affiliates, and production quotas. Kocot Law represents California operators on the federal side and on the DCC-side issues that intersect with it.
Since the window closed: federal guidance posted October 30, 2026 says Timely Applicants and DEA registrants may do business only with each other, with compliant supply chains expected by November 29. The DEA has moved to deny registration to a Minnesota dispensary over its state’s combined medical and adult-use license, and to a D.C. dispensary over patient self-certification. California let retailers split a combined license into separate A and M licenses as of June 4, 2026. And the DEA has said that Schedule III production quotas are being developed for a separate notice. Each of those is covered below.
Call or text (916) 572-6445Ryan Kocot · licensed in California, New York & Massachusetts; federal DEA registration practice. Attorney advertising. Contacting me does not create an attorney-client relationship; please do not send confidential details until we have spoken and confirmed there is no conflict.
Where things stand for a DCC licensee
- If you filed a complete application and fee between April 28 and June 26, 2026: you are a Timely Applicant with conditional operating authority under § 1301.13(k)(7) while the application is pending. The DEA’s published list carries 771 California entries. Under the October 30 guidance you may do business only with other Timely Applicants and DEA registrants, you are expected to verify each one and keep the record, and compliant supply chains are expected by November 29, 2026. What the guidance means and how to check a partner’s status.
- If you filed after June 26: you are in the standard queue with no conditional operating authority, and until the registration issues, Timely Applicants and registrants may not do business with you.
- If you did not file: the standard queue remains open. Your medicinal channel is a Schedule III substance federally whether or not you registered, and your posture as an unregistered operator is a decision to make, not a default to drift into. The unregistered operator’s exposure.
- Either way, the DEA has started saying no. Orders to show cause against a Minnesota dispensary and a D.C. dispensary, and a denial of MedPharm’s bulk-manufacturer application, show the agency reading state licensing frameworks, patient-certification rules, and affiliated-entity control closely. Each has a California analogue, covered below.
To find out where you stand: call or text (916) 572-6445, email Ryan@Kocotlaw.com, or book a consultation.
How § 1301.13(k) reads a DCC license
The April 2026 order rescheduled marijuana to Schedule III only when it is in an FDA-approved drug product or subject to a state medical marijuana license. Adult-use cannabis remains Schedule I. For a California operator that means federal Schedule III status follows the medicinal portion of the operation and nothing else. Under § 1301.13(k)(2), a current DCC license with a medicinal designation is conclusive evidence that the applicant is authorized under state law for the licensed activity. Under § 1301.13(k)(3), the DEA registration suspends automatically if the DCC license is suspended, revoked, or expires, and federal scope can never exceed state scope.
The flipside for California: a DCC enforcement action is now a federal event. An embargo, an emergency order, or an accusation that reaches the license reaches the registration with it. Resolve the state matter before you file, and treat open DCC matters as part of the federal file.
The A/M split, and whether it is enough for the DEA
The single most important federal question for a California operator is the medicinal and adult-use split. A DCC licensee may hold an M designation, an A designation, or both on one premises. The federal rule addresses only medical marijuana licensees, and the DEA has now said, in the Minnesota order to show cause, that a state license authorizing both medical and recreational dispensing does not fit the federal definition of a state medical marijuana license and lacks sufficient protection against diversion. The Minnesota order and what it means here.
California moved first. Emergency regulations effective June 4, 2026 (DCC-2026-03-E) let a qualifying retailer separate a combined license into an A license and a new M license, and on October 30 DCC proposed making them permanent. Under 4 CCR § 15000.2(b), separate entities may hold the two licenses at the same premises if they share the same individual owners and designated responsible party, physically separate cannabis goods by license, keep inventory and track-and-trace records distinct, and maintain separate business records. They are jointly and severally liable for each other’s obligations and violations, and § 15000.1(e) treats them as one licensee for California compliance and enforcement.
That structure answers the formal objection in Minnesota: a separate medical entity holding a medical-only license is a different arrangement from one license covering both. It does not answer the DEA’s broader diversion concern. Whether the agency will accept medical and adult-use businesses at one location, under common ownership, with the separation California requires, is unresolved. Shared employees, shared storage access, shared sales floors, and inventory movement between the two sides are the facts an investigator will look at. DCC’s own notice says the rules give flexibility to businesses pursuing federal registration and that the rulemaking does not establish whether pursuing registration is the right decision or whether a license modification is necessary for approval.
One more data point. In denying MedPharm Research’s bulk-manufacturer application, the DEA looked past the applicant to its parent and sister companies, which shared management and the proposed facility, and treated their recreational production as diversion. A California operator that forms a new M entity should expect the DEA to ask who controls it and what the people in control are doing on the A side. Structure, affiliates, and optionality.
What to do with this: if you hold M+A, the split is a decision with costs on both sides. Not splitting leaves you with the Minnesota objection. Splitting costs money and may not satisfy the DEA on its own. The case for splitting that does not depend on guessing the DEA’s answer is optionality: it keeps every path open while the agency’s position develops. Make it a documented decision, not a default.
Patient certification in California
Section 1301.13(k)(5) accepts a certification or other document that state law deems sufficient for medical access in place of a prescription, so long as it is dated and signed the day it is issued, bears the patient’s full name and address, and carries the name, address, and state license number of the practitioner who signed it. The DEA’s order to show cause against a D.C. dispensary objects to that District’s patient self-certification pathway on exactly this ground: no practitioner signature, no practitioner information. The D.C. order.
California medicinal sales rest on a physician’s recommendation under Health and Safety Code § 11362.5 or a Medical Marijuana Identification Card under § 11362.71. Many dispensary records already meet the federal elements. Some do not, most often because the recommending physician’s Medical Board license number was never captured at the point of sale, or because an older recommendation was verbal or undated. Before filing, and before an inspector asks, a dispensary should review its intake records against the five federal elements and fix the capture going forward. MMIC sales are typically the cleanest predicate.
Mapping a DCC license onto a federal registration
Under § 1301.13(k)(1), registration is granted as a manufacturer, distributor, or dispenser, and one entity may hold more than one. The DCC license type determines which apply:
The application is not a generic cannabis registration. Each registration ties to a specific licensed activity, a specific licensed premises, and the medicinal portion of the operation.
Article 23, and the quotas being developed
California has the largest licensed cultivation footprint in the country, and the federal obligation its growers are least prepared for is Article 23 of the Single Convention, implemented at § 1301.13(k)(6). The manufacturer registration must specify the areas in which cultivation is permitted. Each registrant sets a nominal price for its crop, the DEA buys it at that price and sells it back at the same price plus an administrative fee, and harvested crops must be stored where the DEA has access until that paper transaction is complete. Existing DCC premises diagrams are the starting point for the cultivation-area designation, not the finished product.
Quotas were always part of this framework. The April order directs the DEA to consider treaty requirements, including quota requirements, when it evaluates an application. In a notice scheduled for Federal Register publication on November 10, 2026, the DEA confirmed that it is developing separate production quotas for Schedule III marijuana, marijuana extracts, and naturally derived delta-9-THC, with the amounts to follow in their own notice. A California cultivation license is defined by canopy size and light source. A federal quota is a production quantity tied to estimated legitimate need. The first does not predict the second, and a federal allowance would not let a grower exceed its state tier. What the quota notice does and does not tell us.
METRC, local control, and the premises
Under § 1301.13(k)(4), the DEA accepts state-required reports, records, and forms to the maximum extent permissible. METRC data will likely carry the federal biennial inventory and transfer records. It was not built for Single Convention statistical returns, so a separate federal reporting overlay is likely for manufacturers. The gap review between METRC and Part 1304 is part of every engagement.
Before any of this, the operator needs a valid licensed premises. Business and Professions Code § 26200 lets cities and counties prohibit commercial cannabis activity, DCC will not license what the locality prohibits, and the federal registration cannot exceed the state license. The pre-application checklist begins with the conditional use permit, the local cannabis permit, and the zoning verification.
§ 280E for a California licensee
Schedule III placement removes state-medical-licensed activity from the reach of 26 U.S.C. § 280E prospectively. The AG Order encourages Treasury to consider retrospective relief; none has been issued, and no California operator should plan on it. An M+A licensee remains subject to § 280E on the adult-use side, which turns the separation of cost of goods and operating expense between channels into a tax-accounting matter as well as a compliance one. California’s own conformity rules under Revenue and Taxation Code §§ 17209 and 24436.1 add a state layer. Kocot Law coordinates the federal eligibility analysis and refers the tax work to retained tax counsel.
What the order does not do
Find out where you stand
A short call typically identifies which situation you are in, whether the A/M split is worth making, what your patient-certification records need, the registration categories involved, and the documents to gather. No charge for the initial conversation. Call or text (916) 572-6445, email Ryan@Kocotlaw.com, or book below.
Frequently asked questions
The federal rule does not require it, and a registration can cover the medicinal portion of a combined license. But the DEA’s Minnesota order objects to a single license that authorizes both medical and recreational dispensing, and California now offers a split into separate A and M licenses, including separate entities at the same premises. Whether the split satisfies the DEA is unresolved. It is a decision to make deliberately, with the costs and the open question on the table.
It answers the formal objection. It may not answer the diversion concern. Shared staff, shared storage access, shared sales floors, and inventory movement between the A and M sides are what an investigator will examine, and the MedPharm decision shows the DEA looking at affiliates under common control. Build the separation so it holds under that review, and document it.
You may, depending on which functions handle medicinal product: manufacturer for cultivation and manufacturing, distributor for the internal transfer to your counter, dispenser for retail. One entity may hold all three. The question is whether your medicinal volume justifies three fees and three sets of federal obligations.
Yes. Section 1301.13(k)(5) requires the practitioner’s name, address, and state license number on the certification, signed and dated the day it issued. The D.C. order shows the DEA reading that provision strictly. Review existing records, fix the point-of-sale capture, and treat MMIC sales as the cleanest predicate.
For biennial inventory and transfer records, likely yes under § 1301.13(k)(4). For Single Convention statistical returns, a separate federal reporting overlay will likely be required. A gap review settles which is which for your operation.
No. DCC will not license locally prohibited activity under Business and Professions Code § 26200, and the federal registration cannot exceed the state license. The federal pathway is gated by valid state and local authorization.
Verifying every supplier and buyer against the DEA list and the state license record, keeping the verification ledger, and preparing for the compliance regime that follows registration: security, recordkeeping, inventory, reporting, and inspection. The guidance expects compliant supply chains by November 29, 2026.
No. Interstate movement of marijuana, including state-medical-licensed marijuana, requires import and export permits under 21 U.S.C. §§ 951-971 and 21 C.F.R. § 1312.30. The § 1301.13(k) registration does not include interstate authority.
Under § 1301.13(k)(3), the DEA registration suspends automatically. There is no independent federal status that survives loss of the state license. Resolve open DCC matters before filing.
The DEA has confirmed that separate Schedule III quotas are being developed and will be proposed in their own notice. The amounts and the method are not yet public. Your canopy tier does not predict your federal allowance. Start organizing the records that explain your medicinal production needs now.
The AG Order encourages Treasury to consider it. Nothing has been issued. Plan as if § 280E applies to all pre-rescheduling years and consult tax counsel on any amended-return strategy.
California documents to gather
- Current DCC license or licenses and all amendments, with the M and A designations identified, and any A/M split filings
- DCC premises diagrams, and for cultivators the cultivation-area mapping, light source, and water permits
- Local conditional use permit, business license, or cannabis permit, and zoning verification
- DCC ownership and financial-interest disclosures, and the same for any affiliated entity on the A side
- METRC enterprise structure and badge holders
- For retailers: medicinal-channel SOP, MMIC verification procedure, and physician-recommendation intake records with Medical Board license numbers
- For manufacturers: process flow, extraction equipment, and SOPs for medicinal batches
- For distributors: transport SOP, manifests, and QA records
- For microbusinesses: documentation for each licensed function and the inventory separation plan
- For Timely Applicants: the partner verification ledger and the DEA list entries relied on
- DCC inspection reports, notices to comply, citations, and corrective action plans within the prior three years
- Any pending DCC amendment, ownership change, or change-of-premises application
- Insurance certificates required under Business and Professions Code § 26051.5
What Kocot Law handles
Read the guides
Attorney advertising. This page is general information about federal and California law as of its last review and is not legal advice. Reading it, calling, or submitting a form does not create an attorney-client relationship; none is formed unless and until Kocot Law completes a conflict check and both parties sign an engagement letter. Federal guidance in this area changes frequently; confirm the current state of the rule before relying on any statement here. The order discussed is AG Order No. 6754-2026, 91 Fed. Reg. 22714 (April 28, 2026). Prior results do not guarantee a similar outcome.
Find out where you stand
Free 30-minute consult for California operators: Timely Applicant obligations, the A/M split, patient records, categories, and documents.
Call or text (916) 572-6445 Book a free consultation or email Ryan@Kocotlaw.com